Q-omics provides the consensus-scored SAPCD1 profile across patient tissues and cancer cell-line models. SAPCD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SAPCD1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SAPCD1 RNA expression shows 15,631 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SAPCD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAPCD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAPCD1 survival associations across molecular data types. SAPCD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAPCD1 RNA expression–survival associations across cancer types. High SAPCD1 expression shows unfavorable associations in KIRC, COAD, ACC and LGG, but favorable associations in BLCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SAPCD1 RNA expression.
This table summarizes SAPCD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SAPCD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAPCD1 shows higher tumor expression in COAD, LIHC, BLCA, KIRC, STAD and ESCA. The COAD box plot shows higher SAPCD1 RNA expression in tumor versus normal tissue (log2 FC = +1.097, t-test p < 0.001).
This table shows molecular features associated with SAPCD1 in patient tissues and cancer cell lines. In patient samples, SAPCD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SAPCD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
